Corcept Therapeutics (NASDAQ: CORT) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Corcept Therapeutics to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for Corcept Therapeutics and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics 1 0 4 0 2.60
Corcept Therapeutics Competitors 844 3782 6812 185 2.55

Corcept Therapeutics presently has a consensus target price of $17.80, suggesting a potential downside of 9.60%. As a group, “Pharmaceuticals” companies have a potential upside of 23.79%. Given Corcept Therapeutics’ peers higher probable upside, analysts clearly believe Corcept Therapeutics has less favorable growth aspects than its peers.

Volatility & Risk

Corcept Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Corcept Therapeutics’ peers have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.


This table compares Corcept Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corcept Therapeutics 22.28% 51.45% 33.01%
Corcept Therapeutics Competitors -2,859.89% -68.22% -9.44%

Valuation and Earnings

This table compares Corcept Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Corcept Therapeutics $108.69 million $25.67 million 98.45
Corcept Therapeutics Competitors $8.08 billion $2.63 billion 0.05

Corcept Therapeutics’ peers have higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

62.2% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 19.2% of Corcept Therapeutics shares are owned by insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Corcept Therapeutics beats its peers on 9 of the 13 factors compared.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation’s Abraxane) to treat patients with solid-tumor cancers.

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.